Dr Agarwals Eye Hospital MD, chairman, board of directors and AGM
NSE: DRAGARWQBSE: 526783Healthcare ServicesSmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹4,959.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,443 Cr1,094th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 32.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 7.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 27.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 24.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,32465.1% delivered
Dr Agarwals Eye Hospital board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorAMAR AGARWAL
- Company Secretary and Compliance OfficerMeenakshi Jayaraman
6 directors3 independent2 executive1 non-executive
- AMAR AGARWAL · Chairperson and managing directorExecutive · joined Apr 1994 · 2 listed boards
- ATHIYA AGARWALExecutive · joined May 1994 · 1 listed board
- ADIL AGARWALNon-executive · joined Jun 2019 · 2 listed boards · 2 committee seats, 1 as chair
- VENKATRAMAN BALAKRISHNANIndependent · joined Jun 2022 · reappointed Jun 2022 · 48 months as independent · 2 listed boards · 2 as independent · 3 committee seats, 2 as chair
- LATHA RAMANATHANIndependent · joined May 2024 · reappointed May 2024 · 25 months as independent · 5 listed boards · 5 as independent · 5 committee seats, 2 as chair
- SHIV AGRAWALIndependent · joined Sep 2024 · reappointed Sep 2024 · 21 months as independent · 1 listed board · 1 as independent · 2 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 20 May 20266 of 6 present3 independent · 105 days in between
- 3 Feb 20266 of 6 present3 independent
Audit Committee
Chair VENKATRAMAN BALAKRISHNAN
ADIL AGARWAL, LATHA RAMANATHAN, SHIV AGRAWAL
- 20 May 20264 of 4 present3 independent · 105 days in between
- 3 Feb 20264 of 4 present3 independent
Nomination and remuneration committee
Chair SHIV AGRAWAL
ADIL AGARWAL, LATHA RAMANATHAN, VENKATRAMAN BALAKRISHNAN
- 20 May 20264 of 4 present3 independent · 105 days in between
Stakeholders Relationship Committee
Chair ADIL AGARWAL
SHIV AGRAWAL, LATHA RAMANATHAN, VENKATRAMAN BALAKRISHNAN
- 3 Feb 20264 of 4 present3 independent
Corporate Social Responsibility Committee
Chair ATHIYA AGARWAL
AMAR AGARWAL, SHIV AGRAWAL, LATHA RAMANATHAN
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- S.R. Batliboi & Associates LLPPeer-review certificate valid to Jul 2027
1 earlier auditor
- Deloitte Haskins & SellsNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Dr Agarwals Eye Hospital AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Dr Agarwals Eye Hospital dividend history
Annual general meeting, 9 Sep 2026
22,056 shareholders on the register on 2 Sep 2026; present: 3 promoters and 29 others; votes counted by SUBRAMANIAN CHANDRASEKAR / NA.The company's voting result (opens in a new tab)
- To adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026, along with the Report of the Board of Directors and AuditorsOrdinary99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.12%
Turnout: all 74.92% · promoters 100.00% · institutions 10.13% · other public 7.90%
- To declare a dividend of Rs. 4.00 per Equity share (40%) for the year ended March 31, 2026Ordinary99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.11%
Turnout: all 74.92% · promoters 100.00% · institutions 10.13% · other public 7.90%
- To appoint a director in place of Dr. Adil Agarwal (DIN: 01074272) who retires by rotation and being eligible offers himself for re-appointmentOrdinaryPromoters have an interest in it99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.13%
Turnout: all 74.92% · promoters 100.00% · institutions 10.13% · other public 7.90%
- To ratify the remuneration of Rs. 90,000/- plus applicable taxes and reimbursement of out-of-pocket expenses to the Cost Auditor for the financial year 2025-26Ordinary99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.15%
Turnout: all 74.92% · promoters 100.00% · institutions 10.13% · other public 7.90%
- To approve the revision in remuneration of Dr. Amar Agarwal, Chairman cum Managing Director (DIN: 00435684)SpecialPromoters have an interest in it99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.15%
Turnout: all 74.92% · promoters 100.00% · institutions 10.13% · other public 7.90%
- To approve the revision in remuneration of Dr. Athiya Agarwal, Whole-Time Director (DIN: 01365659)SpecialPromoters have an interest in it99.95% for0.05% against
Against: promoters 0.00% · institutions 0.00% · other public 2.16%
Turnout: all 74.91% · promoters 100.00% · institutions 10.13% · other public 7.86%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 9 Sep 2026, 1 fund house so far (houses' deadline to file 15 Oct 2026)
- To adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026, along with the Report of the Board of Directors and Auditors1 for0 against
- To declare a dividend of Rs. 4.00 per Equity share (40%) for the year ended March 31, 20261 for0 against
- To appoint a director in place of Dr. Adil Agarwal (DIN: 01074272) who retires by rotation and being eligible offers himself for re-appointment1 for0 against
- To ratify the remuneration of Rs. 90,000/- plus applicable taxes and reimbursement of out-of-pocket expenses to the Cost Auditor for the financial year 2025-261 for0 against
- To approve the revision in remuneration of Dr. Amar Agarwal, Chairman cum Managing Director (DIN: 00435684)1 for0 against
- To approve the revision in remuneration of Dr. Athiya Agarwal, Whole-Time Director (DIN: 01365659)1 for0 against
Mutual fund votes, meeting of 2 Jul 2026, 1 fund house so far (houses' deadline to file 15 Oct 2026)
- Scheme of Amalgamation amongst Dr. Agarwal’s Eye Hospital Limited (AEHL) and Dr. Agarwal’s Health Care Limited (AHCL) and their Respective Shareholders and Creditors (Scheme).1 for0 against
1 earlier meeting
Mutual fund votes, meeting of 24 Sep 2025, 2 fund houses
Appointment of M/s. S.R. Batliboi and Associates LLP (EY), Chartered Accountants, Chennai with ICAI Firm Registration No. 101049W/E300004 as the Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the 36th Annual General Meeting of the Company to be held during the year 2030.MoreLess
2 for0 againstAppointment of Mr. Subramanian Chandrasekar, Practicing Company Secretary, Chennai (Membership No. FCS 6773 and COP 13761) as the Secretarial Auditor of the Company for a term of 5 consecutive years, to conduct the Secretarial Audit from the financial year ending March 31, 2026 till March 31, 2030 and to fix their remuneration.MoreLess
2 for0 againstApproval of reappointment of Dr. Amar Agarwal (DIN: 00435684) as the Chairman cum Managing Director of the Company for a period of three years with effect from October 01, 2025 and revision in his remuneration.MoreLess
2 for0 againstApproval of reappointment of Dr. Athiya Agarwal as Whole-Time Director (DIN: 01365659) as the Whole-Time Director of the Company for a period of three years with effect from October 01, 2025 and revision in her remuneration.MoreLess
2 for0 againstRatification of remuneration of Rs. 90,000 plus applicable taxes and reimbursement of out of pocket expenses incurred by them and payable for the year 2024-2025 to M/s. BY and Associates, Cost Accountant in practice (Firm Registration No: 003498) appointed by the Board of Directors of the Company to conduct the audit of the cost records of the Company for the financial year 2024-25.MoreLess
2 for0 against- To appoint a director in the place of Dr. Athiya Agarwal (DIN 01365659) who retires by rotation and being eligible offers herself for reappointment.2 for0 against
To create, offer, issue and allot, on a preferential basis, up to 1,32,827 fully paid up equity shares of the Company having face value of INR 10 each (Equity Shares) for cash, at a price of Rs. 5,270 per Equity Share, which is a price determined in accordance with Chapter V of the ICDR Regulations and for a total consideration of upto Rs. 70,00,00,000, to Dr. Agarwal’s Health Care Limited, promoter of the Company (Promoter Allottee).MoreLess
Against WhiteOak Capital Mutual Fund
- WhiteOak Capital Mutual FundThe company has proposed a merger with the holding company. We are in disagreement with the valuations assigned and hence we do not support the proposed resolution
1 for1 againstTo declare dividend of Rs.3.50 per share (35%) on the paid-up capital consisting of 47,00,000 equity shares, absorbing a sum of Rs. 164.5 lakh as recommended by the Board, be approved and the same for the year ended March 31, 2025.MoreLess
2 for0 against- To receive, consider and adopt the audited financial statement of the Company for the financial year ended March 31, 2025, along with the report of the board of directors and auditors thereon.2 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Tax disputes
Reported in the filing for the quarter to Jun 2026.
- Tax disputeOffice of the Principal Commissioner of CGST and Central ExciseSince 3 May 2025Appeal hearing attended before the office of Commissioner (Appeals). The response is awaited.At the filing before: Appeal hearing attended before the office of Commissioner (Appeals). Additional data request submitted before the Commissioner.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesSep 2025 | 69.99 | – | – | No |